Apollo Global in talks to acquire J&J’s orthopedics unit, Bloomberg News reports
Apollo Global Management is reportedly in talks to acquire Johnson & Johnson's orthopedics unit, DePuy Synthes, for around $20 billion. The unit, which generated $9.3 billion in sales in 2025, is planned to be separated into a standalone company. Bloomberg News cited sources for the report, but Reuters could not verify it. J&J and Apollo Global Management did not comment.
How this was made
The 30-second read
Why it matters
Potential deal could reshape the medical‑device landscape and affect related stocks.
Market read
M&A talks introduce material news for both JNJ and APO, with possible price moves.
What to watch
Regulatory approval risk and integration challenges for JNJ's unit.
Background
Apollo Global Management is exploring acquisition of JNJ's DePuy Synthes orthopedics unit, valued near $20 billion.
Ticker impact
Apollo Global Management is in talks to acquire Johnson & Johnson's orthopedics unit, DePuy Synthes, in a deal valued near $20 billion.
JNJ may face short-term pressure; APO could see modest upside on acquisition rumors.
Deal size and strategic fit are material; market will price in acquisition risk and upside.
Apollo Global Management is reported to be negotiating a $20 billion purchase of JNJ's orthopedics business.
APO could experience a modest rally as investors price in possible transaction.
Large‑scale M&A news typically moves the acquirer’s stock, especially for a private‑equity firm.
Market effects
Consolidation in medical devices could pressure other orthopedics peers.
U.S. healthcare sector may see valuation adjustments.
Large M&A could influence global private‑equity activity.
Counterpoint
Deal may fall apart, leaving both stocks unchanged.
Key entities
- CompanyJohnson & Johnson
Owner of DePuy Synthes orthopedics unit.
- CompanyApollo Global Management
Private‑equity firm pursuing the acquisition.
